In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA
Sponsored by
